Cargando…

Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity

Adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD(+)) are released as danger signals from cells during infection and sterile inflammation. In the extracellular compartment ATP is converted by CD39, CD73, and other ecto-enzymes into metabolites that modulate the activity of T ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menzel, Stephan, Schwarz, Nicole, Haag, Friedrich, Koch-Nolte, Friedrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880931/ https://www.ncbi.nlm.nih.gov/pubmed/29636685 http://dx.doi.org/10.3389/fphar.2018.00266

Ejemplares similares

Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo
por: Demeules, Mélanie, et al.
Publicado: (2022)

Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs
por: Pinto-Espinoza, Carolina, et al.
Publicado: (2022)

A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation
por: Eden, Thomas, et al.
Publicado: (2018)

Nanobodies as modulators of inflammation: potential applications for acute brain injury
por: Rissiek, Björn, et al.
Publicado: (2014)

Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD(+) Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
por: Baum, Natalie, et al.
Publicado: (2020)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)

Use of Humanized Mouse Models to Investigate the Roles of Purinergic Signaling in Inflammation and Immunity
por: Sluyter, Ronald, et al.
Publicado: (2020)

ADP-Ribosylation Regulates the Signaling Function of IFN-γ
por: Menzel, Stephan, et al.
Publicado: (2021)

Purinergic Signalling: Therapeutic Developments
por: Burnstock, Geoffrey
Publicado: (2017)

Signaling of the Purinergic System in the Joint
por: Corciulo, Carmen, et al.
Publicado: (2020)

Editorial: Purinergic signaling and neuroinflammation
por: Assmann, Charles Elias, et al.
Publicado: (2022)

Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT
por: Unger, Mandy, et al.
Publicado: (2015)

Editorial: Emerging Mechanisms in Purinergic Signaling: From Cell Biology to Therapeutic Perspectives
por: Gomez-Villafuertes, Rosa, et al.
Publicado: (2020)

Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors
por: Eichhoff, Anna Marei, et al.
Publicado: (2019)

Nanobodies: new avenue to treat kidney disease
por: Wanner, Nicola, et al.
Publicado: (2021)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Purinergic signaling in the modulation of redox biology
por: Savio, Luiz Eduardo Baggio, et al.
Publicado: (2021)

Biology of Platelet Purinergic Receptors and Implications for Platelet Heterogeneity
por: Koupenova, Milka, et al.
Publicado: (2018)

Origin, distribution, and function of three frequent coding polymorphisms in the gene for the human P2X7 ion channel
por: Schäfer, Waldemar, et al.
Publicado: (2022)

Purinergic Signaling in Mast Cell Degranulation and Asthma
por: Gao, Zhan-Guo, et al.
Publicado: (2017)

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
por: Bannas, Peter, et al.
Publicado: (2015)

Control of Gut Inflammation by Modulation of Purinergic Signaling
por: Vuerich, Marta, et al.
Publicado: (2020)

Generation and Characterization of Specific Monoclonal Antibodies and Nanobodies Directed Against the ATP-Gated Channel P2X4
por: Bergmann, Philine, et al.
Publicado: (2019)

Targeting Purinergic Signaling in the Dynamics of Disease Progression in Sepsis
por: Leite-Aguiar, Raíssa, et al.
Publicado: (2021)

Editorial: Purinergic Pharmacology
por: Ciruela, Francisco, et al.
Publicado: (2019)

Metabolic Changes Induced by Purinergic Signaling: Role in Food Intake
por: Caruso, Vanni, et al.
Publicado: (2021)

Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis
por: Nobili, Paola, et al.
Publicado: (2022)

Purinergic signaling: A gatekeeper of blood-brain barrier permeation
por: Wang, Yuemei, et al.
Publicado: (2023)

Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases
por: Dal Ben, Diego, et al.
Publicado: (2018)

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
por: Schriewer, Levin, et al.
Publicado: (2020)

Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano)
por: Demeules, Mélanie, et al.
Publicado: (2020)

Extracellular NAD and ATP: Partners in immune cell modulation
por: Haag, Friedrich, et al.
Publicado: (2007)

Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy
por: Jank, Larissa, et al.
Publicado: (2019)

The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation
por: Di Liberto, Valentina, et al.
Publicado: (2016)

Purinergic Signaling in Pulmonary Inflammation
por: Le, Thanh-Thuy T., et al.
Publicado: (2019)

Editorial: Purinergic Signaling and Inflammation
por: Yuan, Xiaoyi, et al.
Publicado: (2021)

Purinergic P2X7 receptor antagonist ameliorates intestinal inflammation in postoperative ileus
por: KIMURA, Hitomi, et al.
Publicado: (2022)

Editorial: Purinergic pharmacology, Volume II
por: Ciruela, Francisco, et al.
Publicado: (2023)

Tuning IL-2 signaling by ADP-ribosylation of CD25
por: Teege, Sophie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j9693nfvd464qhlepos39n7k1g